Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Public ClinicalTrials.gov record NCT06810050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Effectiveness of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.
Study identification
- NCT ID
- NCT06810050
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2024
- Primary completion
- Aug 29, 2025
- Completion
- Oct 29, 2025
- Last update posted
- Apr 1, 2026
2024 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center for Dermatology Clinical Research Inc. | Fremont | California | 94538 | — |
| Ablon Skin Institute and Research Center | Manhattan Beach | California | 90266 | — |
| TCR Medical Corporation | San Diego | California | 92123 | — |
| Syrentis Clinical Research | Santa Ana | California | 92705 | — |
| USA and International Research Inc. | Doral | Florida | 33126 | — |
| FXM Clinical Research | Fort Lauderdale | Florida | 33308 | — |
| Driven Research | Gables | Florida | 33134 | — |
| FXM Clinical Research Miami, LLC | Miami | Florida | 33175 | — |
| FXM Clinical Research Miramar, LLC | Miramar | Florida | 33027 | — |
| Cordova Research Institute | Sweetwater | Florida | 33182 | — |
| The Indiana Clinical Trials Center, PC | Plainfield | Indiana | 46168 | — |
| Metro Boston Clinical Partners | Brighton | Massachusetts | 02135 | — |
| J&S Studies, Inc. | New Brighton | Minnesota | 55112 | — |
| JDR Dermatology Research | Las Vegas | Nevada | 89148 | — |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37215 | — |
| DermResearch | Austin | Texas | 78759 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06810050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06810050 live on ClinicalTrials.gov.